董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Behzad Aghazadeh | 男 | Director | 54 | 未披露 | 69.77 | 2026-07-15 |
| Benjamin L. Oakes | 男 | President, Chief Executive Officer and Chairman of the Board and Director | 37 | 158.88万美元 | 66.10 | 2026-07-15 |
| James Watson | 男 | Director | 61 | 未披露 | 未持股 | 2026-07-15 |
| Joshua Bleharski | 男 | Director | 51 | 未披露 | 未持股 | 2026-07-15 |
| Carl L. Gordon | 男 | Director | 61 | 未披露 | 34.88 | 2026-07-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Svetlana Lucas | 女 | Chief Operating Officer | 54 | 78.76万美元 | 11.43 | 2026-07-15 |
| Benjamin L. Oakes | 男 | President, Chief Executive Officer and Chairman of the Board and Director | 37 | 158.88万美元 | 66.10 | 2026-07-15 |
| David L. Parrot | 男 | Chief Financial Officer | 57 | 98.47万美元 | 11.49 | 2026-07-15 |
董事简历
中英对照 | 中文 | 英文- Behzad Aghazadeh
-
Behzad Aghazadeh，自2021年3月起担任Scribe Therapeutics，Inc.董事会成员，现任Avoro Capital Advisors和Avoro Ventures管理合伙人。Avoro Capital是一家全球生命科学公司，他于2011年7月加入该公司。从2017年3月到2020年10月，Aghazadeh博士还担任上市生物制药公司Immunomedics, Inc.（现为吉利德科学公司的子公司）的董事会执行主席。Aghazadeh博士还担任Whitehawk Therapeutics，Inc.的董事会成员，该公司是一家商业阶段的生物制药公司，专注于基因定义癌症的精准疗法。Aghazadeh博士在生物制药行业拥有超过20年的经验，其中包括超过15年的机构投资者经验，此前曾在Booz Allen担任过6年的医疗保健领域高级管理团队的一般管理顾问。Aghazadeh博士获得了慕尼黑Ludwig Maximilian大学的物理学硕士学位和康奈尔大学的生物化学和生物物理学博士学位。
Behzad Aghazadeh,has served as a member of Scribe Therapeutics, Inc. board of directors since March 2021, and is currently the Managing Partner of Avoro Capital Advisors and Avoro Ventures. Avoro Capital is a global life sciences company, which he joined in July 2011. From March 2017 to October 2020, Dr. Aghazadeh also served as Executive Chairman of the board of directors of Immunomedics, Inc., a public biopharmaceutical company (now a subsidiary of Gilead Sciences, Inc.). Dr. Aghazadeh additionally serves on the board of directors of Whitehawk Therapeutics, Inc., a commercial-stage biopharmaceutical company, which focuses on precision therapies for genetically defined cancers. Dr. Aghazadeh has more than 20 years of experience in the biopharmaceutical industry, including more than 15 years as an institutional investor and previously six years at Booz Allen as a general management consultant to senior executive teams in the healthcare sector. Dr. Aghazadeh received an M.S. in Physics from Ludwig Maximilian University of Munich and a Ph.D. in Biochemistry and Biophysics from Cornell University. - Behzad Aghazadeh，自2021年3月起担任Scribe Therapeutics，Inc.董事会成员，现任Avoro Capital Advisors和Avoro Ventures管理合伙人。Avoro Capital是一家全球生命科学公司，他于2011年7月加入该公司。从2017年3月到2020年10月，Aghazadeh博士还担任上市生物制药公司Immunomedics, Inc.（现为吉利德科学公司的子公司）的董事会执行主席。Aghazadeh博士还担任Whitehawk Therapeutics，Inc.的董事会成员，该公司是一家商业阶段的生物制药公司，专注于基因定义癌症的精准疗法。Aghazadeh博士在生物制药行业拥有超过20年的经验，其中包括超过15年的机构投资者经验，此前曾在Booz Allen担任过6年的医疗保健领域高级管理团队的一般管理顾问。Aghazadeh博士获得了慕尼黑Ludwig Maximilian大学的物理学硕士学位和康奈尔大学的生物化学和生物物理学博士学位。
- Behzad Aghazadeh,has served as a member of Scribe Therapeutics, Inc. board of directors since March 2021, and is currently the Managing Partner of Avoro Capital Advisors and Avoro Ventures. Avoro Capital is a global life sciences company, which he joined in July 2011. From March 2017 to October 2020, Dr. Aghazadeh also served as Executive Chairman of the board of directors of Immunomedics, Inc., a public biopharmaceutical company (now a subsidiary of Gilead Sciences, Inc.). Dr. Aghazadeh additionally serves on the board of directors of Whitehawk Therapeutics, Inc., a commercial-stage biopharmaceutical company, which focuses on precision therapies for genetically defined cancers. Dr. Aghazadeh has more than 20 years of experience in the biopharmaceutical industry, including more than 15 years as an institutional investor and previously six years at Booz Allen as a general management consultant to senior executive teams in the healthcare sector. Dr. Aghazadeh received an M.S. in Physics from Ludwig Maximilian University of Munich and a Ph.D. in Biochemistry and Biophysics from Cornell University.
- Benjamin L. Oakes
-
Benjamin L. Oakes是Scribe Therapeutics，Inc.的联合创始人，自Scribe Therapeutics，Inc.于2017年6月成立以来，一直担任Scribe Therapeutics，Inc.的首席执行官、总裁以及Scribe Therapeutics，Inc.的董事会成员。在2017年6月共同创立公司之前，Oakes博士于2017年5月至2018年9月担任创新基因组学研究所的创业研究员，在那里他专注于基因组编辑技术的整体工程，以构建新的基因组编辑分子。奥克斯博士拥有科尔比学院哲学和神经生物学学士学位，并拥有加州大学伯克利分校分子和细胞生物学博士学位。
Benjamin L. Oakes,is Scribe Therapeutics, Inc. co-founder and has served as Scribe Therapeutics, Inc. Chief Executive Officer, President, and a member of Scribe Therapeutics, Inc. board of directors since Scribe Therapeutics, Inc. inception in June 2017. Prior to co-founding the Company in June 2017, Dr. Oakes served as an Entrepreneurial Fellow at the Innovative Genomics Institute from May 2017 to September 2018, where he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Dr. Oakes holds a B.A. in Philosophy and Neurobiology from Colby College and holds a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley. - Benjamin L. Oakes是Scribe Therapeutics，Inc.的联合创始人，自Scribe Therapeutics，Inc.于2017年6月成立以来，一直担任Scribe Therapeutics，Inc.的首席执行官、总裁以及Scribe Therapeutics，Inc.的董事会成员。在2017年6月共同创立公司之前，Oakes博士于2017年5月至2018年9月担任创新基因组学研究所的创业研究员，在那里他专注于基因组编辑技术的整体工程，以构建新的基因组编辑分子。奥克斯博士拥有科尔比学院哲学和神经生物学学士学位，并拥有加州大学伯克利分校分子和细胞生物学博士学位。
- Benjamin L. Oakes,is Scribe Therapeutics, Inc. co-founder and has served as Scribe Therapeutics, Inc. Chief Executive Officer, President, and a member of Scribe Therapeutics, Inc. board of directors since Scribe Therapeutics, Inc. inception in June 2017. Prior to co-founding the Company in June 2017, Dr. Oakes served as an Entrepreneurial Fellow at the Innovative Genomics Institute from May 2017 to September 2018, where he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Dr. Oakes holds a B.A. in Philosophy and Neurobiology from Colby College and holds a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley.
- James Watson
-
James Watson，自2025年7月起担任Scribe Therapeutics，Inc.董事会成员，目前是Andreessen Horowitz的Bio + Health团队的运营合伙人，领导该公司在生命科学领域的业务和企业发展团队。沃森先生还在Inceptive、Genesis Molecular AI和Rice Biotech Labs的董事会任职。从2019年10月到2023年3月，沃森先生担任Carmot Therapeutics，Inc.的首席商务官，领导战略、财务和企业发展。自2018年4月至2019年7月，Watson先生在礼来公司收购TERM3公司之前，在Sigilon Therapeutics, Inc.或Sigilon担任首席业务官兼ICT总裁。此前，沃森先生在生命科学投资银行工作了近十年，并领导了两家上市生物技术公司的企业发展。沃森先生在英国朴茨茅斯大学获得经济学学士学位，并在印第安纳大学获得MBA学位。
James Watson,has served as a member of Scribe Therapeutics, Inc. board of directors since July 2025, and is currently an Operating Partner on the Bio + Health team at Andreessen Horowitz and leads the firm's Business and Corporate Development team in life sciences. Mr. Watson also serves on the Boards of Inceptive, Genesis Molecular AI and Rice Biotech Labs. From October 2019 to March 2023, Mr. Watson served as the Chief Business Officer for Carmot Therapeutics, Inc. where he led strategy, finance, and corporate development. From April 2018 to July 2019, Mr. Watson served as Chief Business Officer and President ICT at Sigilon Therapeutics, Inc., or Sigilon, prior to Sigilon's acquisition by Eli Lilly and Company. Previously, Mr. Watson spent nearly ten years in life science investment banking and led corporate development for two public biotechnology companies. Mr. Watson earned a bachelor's degree in economics from the University of Portsmouth, United Kingdom and an MBA from Indiana University. - James Watson，自2025年7月起担任Scribe Therapeutics，Inc.董事会成员，目前是Andreessen Horowitz的Bio + Health团队的运营合伙人，领导该公司在生命科学领域的业务和企业发展团队。沃森先生还在Inceptive、Genesis Molecular AI和Rice Biotech Labs的董事会任职。从2019年10月到2023年3月，沃森先生担任Carmot Therapeutics，Inc.的首席商务官，领导战略、财务和企业发展。自2018年4月至2019年7月，Watson先生在礼来公司收购TERM3公司之前，在Sigilon Therapeutics, Inc.或Sigilon担任首席业务官兼ICT总裁。此前，沃森先生在生命科学投资银行工作了近十年，并领导了两家上市生物技术公司的企业发展。沃森先生在英国朴茨茅斯大学获得经济学学士学位，并在印第安纳大学获得MBA学位。
- James Watson,has served as a member of Scribe Therapeutics, Inc. board of directors since July 2025, and is currently an Operating Partner on the Bio + Health team at Andreessen Horowitz and leads the firm's Business and Corporate Development team in life sciences. Mr. Watson also serves on the Boards of Inceptive, Genesis Molecular AI and Rice Biotech Labs. From October 2019 to March 2023, Mr. Watson served as the Chief Business Officer for Carmot Therapeutics, Inc. where he led strategy, finance, and corporate development. From April 2018 to July 2019, Mr. Watson served as Chief Business Officer and President ICT at Sigilon Therapeutics, Inc., or Sigilon, prior to Sigilon's acquisition by Eli Lilly and Company. Previously, Mr. Watson spent nearly ten years in life science investment banking and led corporate development for two public biotechnology companies. Mr. Watson earned a bachelor's degree in economics from the University of Portsmouth, United Kingdom and an MBA from Indiana University.
- Joshua Bleharski
-
Joshua Bleharski，自2026年7月起担任董事会成员。Bleharski博士目前是IDEAYA生物科学，Inc.的首席财务官，该公司是一家精准医学肿瘤学公司，他于2025年5月加入该公司。在此之前，Bleharski博士曾于2008年7月至2025年4月在摩根大通的医疗保健投资银行集团担任过多种职务，最近担任生物制药公司的董事总经理和全球联席主管。在他的银行业生涯中，Bleharski博士为价值超过650亿美元的交易提供咨询，重点是资本市场交易、并购和公司战略。Bleharski博士在杜克大学获得生物学学士学位，在加州大学伯克利哈斯商学院获得工商管理硕士学位，在加州大学洛杉矶分校获得微生物学和免疫学博士学位。
Joshua Bleharski,has served as a member of board of directors since July 2026. Dr. Bleharski is currently the chief financial officer of IDEAYA Biosciences, Inc., a precision medicine oncology company, which he joined in May 2025. Prior to that, Dr. Bleharski served in a variety of roles at J.P Morgan's Healthcare Investment Banking group from July 2008 to April 2025, most recently as a Managing Director and Global Co-Head of Biopharma. Over the course of his banking career, Dr. Bleharski advised on deals representing more than $65 billion of value, with a focus on capital markets transactions, M&A, and corporate strategy. Dr. Bleharski received a B.S. in Biology from Duke University, an M.B.A. from the University of California, Berkeley Haas School of Business, and a Ph.D. in Microbiology & Immunology from the University of California, Los Angeles. - Joshua Bleharski，自2026年7月起担任董事会成员。Bleharski博士目前是IDEAYA生物科学，Inc.的首席财务官，该公司是一家精准医学肿瘤学公司，他于2025年5月加入该公司。在此之前，Bleharski博士曾于2008年7月至2025年4月在摩根大通的医疗保健投资银行集团担任过多种职务，最近担任生物制药公司的董事总经理和全球联席主管。在他的银行业生涯中，Bleharski博士为价值超过650亿美元的交易提供咨询，重点是资本市场交易、并购和公司战略。Bleharski博士在杜克大学获得生物学学士学位，在加州大学伯克利哈斯商学院获得工商管理硕士学位，在加州大学洛杉矶分校获得微生物学和免疫学博士学位。
- Joshua Bleharski,has served as a member of board of directors since July 2026. Dr. Bleharski is currently the chief financial officer of IDEAYA Biosciences, Inc., a precision medicine oncology company, which he joined in May 2025. Prior to that, Dr. Bleharski served in a variety of roles at J.P Morgan's Healthcare Investment Banking group from July 2008 to April 2025, most recently as a Managing Director and Global Co-Head of Biopharma. Over the course of his banking career, Dr. Bleharski advised on deals representing more than $65 billion of value, with a focus on capital markets transactions, M&A, and corporate strategy. Dr. Bleharski received a B.S. in Biology from Duke University, an M.B.A. from the University of California, Berkeley Haas School of Business, and a Ph.D. in Microbiology & Immunology from the University of California, Los Angeles.
- Carl L. Gordon
-
Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
- Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
高管简历
中英对照 | 中文 | 英文- Svetlana Lucas
Svetlana Lucas，自2026年7月起担任Scribe Therapeutics，Inc.首席运营官，此前自2019年6月起担任Scribe Therapeutics，Inc.首席商务官。在加入Scribe Therapeutics，Inc.之前，Lucas博士曾于2015年7月至2019年6月在Tizona Therapeutics，Inc.或Tizona担任多个职责日益增加的职位，包括最近于2019年1月至2019年6月担任业务发展高级副总裁。在加入Tizona之前，Dr. Lucas于2014年8月至2015年7月在安进公司或安进担任肿瘤学和炎症外部研发主管。Lucas博士在安进收购奥尼斯医药（Onyx）后加入安进，她于2012年9月至2014年8月期间担任企业发展总监。在加入Onyx之前，Lucas博士曾在XOMA公司、Facet Biotech（被艾伯维收购）、PDL Biopharma，Inc.和安进担任战略、业务发展和战略营销方面的职责越来越重的职位。卢卡斯博士的职业生涯始于麦肯锡公司生命科学业务的战略顾问。Lucas博士自2024年6月起担任上市生物技术公司Jasper Therapeutics, Inc.的董事会成员，自2019年7月起担任上市生物制药公司aTyr制药，Inc.的董事会成员。自2023年10月以来，卢卡斯博士还担任Radar Therapeutics的顾问。Lucas博士拥有罗蒙诺索夫莫斯科国立大学生物学本科学位，并拥有加州理工学院分子生物学和生物化学博士学位。
Svetlana Lucas,has served as Scribe Therapeutics, Inc. Chief Operating Officer since July 2026 and previously served as Scribe Therapeutics, Inc. Chief Business Officer since June 2019. Prior to joining Scribe Therapeutics, Inc., Dr. Lucas served in various positions of increasing responsibility at Tizona Therapeutics, Inc., or Tizona, from July 2015 to June 2019, including most recently as Senior Vice President, Business Development from January 2019 to June 2019. Before joining Tizona, Dr. Lucas served as Head of Oncology and Inflammation External Research and Development at Amgen Inc., or Amgen, from August 2014 to July 2015. Dr. Lucas joined Amgen following Amgen's acquisition of Onyx Pharmaceuticals, Inc., or Onyx, where she served as the Director of Corporate Development from September 2012 to August 2014. Prior to joining Onyx, Dr. Lucas held positions of increasing responsibility in strategy, business development and strategic marketing at XOMA Corporation, Facet Biotech (acquired by AbbVie), PDL Biopharma, Inc., and Amgen. Dr. Lucas began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Dr. Lucas has served as a member of the boards of directors of Jasper Therapeutics, Inc., a public biotechnology company, since June 2024, and aTyr Pharma, Inc., a public biopharmaceutical company, since July 2019. Dr. Lucas has also served as an advisor to Radar Therapeutics since October 2023. Dr. Lucas holds an undergraduate degree in Biology from Lomonosov Moscow State University and holds a Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology.- Svetlana Lucas，自2026年7月起担任Scribe Therapeutics，Inc.首席运营官，此前自2019年6月起担任Scribe Therapeutics，Inc.首席商务官。在加入Scribe Therapeutics，Inc.之前，Lucas博士曾于2015年7月至2019年6月在Tizona Therapeutics，Inc.或Tizona担任多个职责日益增加的职位，包括最近于2019年1月至2019年6月担任业务发展高级副总裁。在加入Tizona之前，Dr. Lucas于2014年8月至2015年7月在安进公司或安进担任肿瘤学和炎症外部研发主管。Lucas博士在安进收购奥尼斯医药（Onyx）后加入安进，她于2012年9月至2014年8月期间担任企业发展总监。在加入Onyx之前，Lucas博士曾在XOMA公司、Facet Biotech（被艾伯维收购）、PDL Biopharma，Inc.和安进担任战略、业务发展和战略营销方面的职责越来越重的职位。卢卡斯博士的职业生涯始于麦肯锡公司生命科学业务的战略顾问。Lucas博士自2024年6月起担任上市生物技术公司Jasper Therapeutics, Inc.的董事会成员，自2019年7月起担任上市生物制药公司aTyr制药，Inc.的董事会成员。自2023年10月以来，卢卡斯博士还担任Radar Therapeutics的顾问。Lucas博士拥有罗蒙诺索夫莫斯科国立大学生物学本科学位，并拥有加州理工学院分子生物学和生物化学博士学位。
- Svetlana Lucas,has served as Scribe Therapeutics, Inc. Chief Operating Officer since July 2026 and previously served as Scribe Therapeutics, Inc. Chief Business Officer since June 2019. Prior to joining Scribe Therapeutics, Inc., Dr. Lucas served in various positions of increasing responsibility at Tizona Therapeutics, Inc., or Tizona, from July 2015 to June 2019, including most recently as Senior Vice President, Business Development from January 2019 to June 2019. Before joining Tizona, Dr. Lucas served as Head of Oncology and Inflammation External Research and Development at Amgen Inc., or Amgen, from August 2014 to July 2015. Dr. Lucas joined Amgen following Amgen's acquisition of Onyx Pharmaceuticals, Inc., or Onyx, where she served as the Director of Corporate Development from September 2012 to August 2014. Prior to joining Onyx, Dr. Lucas held positions of increasing responsibility in strategy, business development and strategic marketing at XOMA Corporation, Facet Biotech (acquired by AbbVie), PDL Biopharma, Inc., and Amgen. Dr. Lucas began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Dr. Lucas has served as a member of the boards of directors of Jasper Therapeutics, Inc., a public biotechnology company, since June 2024, and aTyr Pharma, Inc., a public biopharmaceutical company, since July 2019. Dr. Lucas has also served as an advisor to Radar Therapeutics since October 2023. Dr. Lucas holds an undergraduate degree in Biology from Lomonosov Moscow State University and holds a Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology.
- Benjamin L. Oakes
Benjamin L. Oakes是Scribe Therapeutics，Inc.的联合创始人，自Scribe Therapeutics，Inc.于2017年6月成立以来，一直担任Scribe Therapeutics，Inc.的首席执行官、总裁以及Scribe Therapeutics，Inc.的董事会成员。在2017年6月共同创立公司之前，Oakes博士于2017年5月至2018年9月担任创新基因组学研究所的创业研究员，在那里他专注于基因组编辑技术的整体工程，以构建新的基因组编辑分子。奥克斯博士拥有科尔比学院哲学和神经生物学学士学位，并拥有加州大学伯克利分校分子和细胞生物学博士学位。
Benjamin L. Oakes,is Scribe Therapeutics, Inc. co-founder and has served as Scribe Therapeutics, Inc. Chief Executive Officer, President, and a member of Scribe Therapeutics, Inc. board of directors since Scribe Therapeutics, Inc. inception in June 2017. Prior to co-founding the Company in June 2017, Dr. Oakes served as an Entrepreneurial Fellow at the Innovative Genomics Institute from May 2017 to September 2018, where he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Dr. Oakes holds a B.A. in Philosophy and Neurobiology from Colby College and holds a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley.- Benjamin L. Oakes是Scribe Therapeutics，Inc.的联合创始人，自Scribe Therapeutics，Inc.于2017年6月成立以来，一直担任Scribe Therapeutics，Inc.的首席执行官、总裁以及Scribe Therapeutics，Inc.的董事会成员。在2017年6月共同创立公司之前，Oakes博士于2017年5月至2018年9月担任创新基因组学研究所的创业研究员，在那里他专注于基因组编辑技术的整体工程，以构建新的基因组编辑分子。奥克斯博士拥有科尔比学院哲学和神经生物学学士学位，并拥有加州大学伯克利分校分子和细胞生物学博士学位。
- Benjamin L. Oakes,is Scribe Therapeutics, Inc. co-founder and has served as Scribe Therapeutics, Inc. Chief Executive Officer, President, and a member of Scribe Therapeutics, Inc. board of directors since Scribe Therapeutics, Inc. inception in June 2017. Prior to co-founding the Company in June 2017, Dr. Oakes served as an Entrepreneurial Fellow at the Innovative Genomics Institute from May 2017 to September 2018, where he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Dr. Oakes holds a B.A. in Philosophy and Neurobiology from Colby College and holds a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley.
- David L. Parrot
David L. Parrot自2021年12月起担任Scribe Therapeutics，Inc.的首席财务官。在加入Scribe Therapeutics，Inc.之前，Parrot先生于2019年3月至2021年12月在巴克莱银行投资银行（巴克莱银行）担任董事总经理兼西海岸生命科学投资银行部门主管。在加入巴克莱银行之前，Parrot先生于2014年12月至2019年3月在SunTrust Robinson Humphrey（即SunTrust）担任董事总经理兼生命科学投资银行业务主管。在加入SunTrust之前，Parrot先生于2010年7月至2014年12月在BMO资本市场担任生命科学投资银行业务董事总经理，于2009年6月至2010年7月在Montgomery & Co.，LLC担任医疗保健投资银行业务董事总经理，并于1998年6月至2009年6月在Piper Jaffray担任董事总经理。Parrot先生拥有米德尔伯里学院的经济学学士学位，并拥有加州大学伯克利分校哈斯商学院的MBA学位。
David L. Parrot,has served as Scribe Therapeutics, Inc. Chief Financial Officer since December 2021. Prior to joining Scribe Therapeutics, Inc., Mr. Parrot served as a Managing Director and Head of West Coast Life Science Investment Banking division at Barclays Investment Bank, or Barclays, from March 2019 to December 2021. Prior to joining Barclays, Mr. Parrot served as a Managing Director and Head of Life Sciences Investment Banking at SunTrust Robinson Humphrey, or SunTrust, from December 2014 to March 2019. Prior to SunTrust, Mr. Parrot served as a Managing Director of Life Science Investment Banking at BMO Capital Markets from July 2010 to December 2014, as a Managing Director of Healthcare Investment Banking for Montgomery & Co., LLC from June 2009 to July 2010, and as a Managing Director for Piper Jaffray from June 1998 to June 2009. Mr. Parrot holds a B.A. in Economics from Middlebury College and holds an MBA from the University of California, Berkeley, Haas School of Business.- David L. Parrot自2021年12月起担任Scribe Therapeutics，Inc.的首席财务官。在加入Scribe Therapeutics，Inc.之前，Parrot先生于2019年3月至2021年12月在巴克莱银行投资银行（巴克莱银行）担任董事总经理兼西海岸生命科学投资银行部门主管。在加入巴克莱银行之前，Parrot先生于2014年12月至2019年3月在SunTrust Robinson Humphrey（即SunTrust）担任董事总经理兼生命科学投资银行业务主管。在加入SunTrust之前，Parrot先生于2010年7月至2014年12月在BMO资本市场担任生命科学投资银行业务董事总经理，于2009年6月至2010年7月在Montgomery & Co.，LLC担任医疗保健投资银行业务董事总经理，并于1998年6月至2009年6月在Piper Jaffray担任董事总经理。Parrot先生拥有米德尔伯里学院的经济学学士学位，并拥有加州大学伯克利分校哈斯商学院的MBA学位。
- David L. Parrot,has served as Scribe Therapeutics, Inc. Chief Financial Officer since December 2021. Prior to joining Scribe Therapeutics, Inc., Mr. Parrot served as a Managing Director and Head of West Coast Life Science Investment Banking division at Barclays Investment Bank, or Barclays, from March 2019 to December 2021. Prior to joining Barclays, Mr. Parrot served as a Managing Director and Head of Life Sciences Investment Banking at SunTrust Robinson Humphrey, or SunTrust, from December 2014 to March 2019. Prior to SunTrust, Mr. Parrot served as a Managing Director of Life Science Investment Banking at BMO Capital Markets from July 2010 to December 2014, as a Managing Director of Healthcare Investment Banking for Montgomery & Co., LLC from June 2009 to July 2010, and as a Managing Director for Piper Jaffray from June 1998 to June 2009. Mr. Parrot holds a B.A. in Economics from Middlebury College and holds an MBA from the University of California, Berkeley, Haas School of Business.